For instance, genomic alternations such as specific mutations in breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2) genes are well-established tumor biomarkers used for breast cancer risk assessment, meaning that women bearing these mutations are predisposed to develop breast cancer [16,17]. This evidence concerns the gene BRCA1 and breast cancer.